Floatz logo

T-Cell Receptor-Engineered T-Cells

Solid and Hematological Malignancies

AdaptimmuneCell therapyDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1412 Active assets in the Solid and Hematological Malignancies cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Inno-206
M.D. Anderson Cancer Center
Phase 2BB
Vitamin B6
M.D. Anderson Cancer Center
Phase 4BB
PROPOFOL
Hong Kong Children's Hospital
Phase 4BB
Rivoceranib
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BB

View all 50 →

Same molecule, other indications

T-Cell Receptor-Engineered T-Cells is also rated in:

prostate small cell carcinomaDormant
CC
Indicative ·
40 / 100
View asset →
prostate cancerDormant
CC
Indicative ·
40 / 100
View asset →
prostate carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →